Crispr Therapeutics Ag CRSP
We take great care to ensure that the data presented and summarized in this overview for CRISPR Therapeutics AG is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRSP
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$389 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$379 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$165 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$120 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$119 Million1.21% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$119 Million0.07% of portfolio
-
State Street Corp Boston, MA2.49MShares$108 Million0.0% of portfolio
-
Ubs Group Ag1.98MShares$85.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$75.2 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD1.59MShares$68.8 Million4.46% of portfolio
Latest Institutional Activity in CRSP
Top Purchases
Top Sells
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Transactions at CRSP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 12
2025
|
Julianne Bruno Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
190
-2.18%
|
$8,170
$43.32 P/Share
|
Mar 12
2025
|
James R. Kasinger General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
1,116
-1.4%
|
$47,988
$43.32 P/Share
|
Mar 12
2025
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,462
-2.35%
|
$191,866
$43.32 P/Share
|
Mar 11
2025
|
Julianne Bruno Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
435
+4.76%
|
-
|
Mar 11
2025
|
Julianne Bruno Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,198
-12.66%
|
$50,316
$42.42 P/Share
|
Mar 11
2025
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+2.74%
|
-
|
Mar 11
2025
|
James R. Kasinger General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
2,850
-3.55%
|
$119,700
$42.42 P/Share
|
Mar 11
2025
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+4.53%
|
-
|
Mar 11
2025
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,973
-5.23%
|
$418,866
$42.42 P/Share
|
Mar 10
2025
|
Julianne Bruno Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,399
+20.23%
|
-
|
Mar 10
2025
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+6.4%
|
-
|
Mar 10
2025
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,250
+9.16%
|
-
|
Feb 26
2025
|
John Greene |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$308,000
$44.85 P/Share
|
Feb 19
2025
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,288
-6.59%
|
$1,365,552
$54.0 P/Share
|
Feb 19
2025
|
James R. Kasinger General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
1,947
-2.53%
|
$101,244
$52.8 P/Share
|
Feb 19
2025
|
Julianne Bruno Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
333
-4.5%
|
$17,316
$52.8 P/Share
|
Feb 18
2025
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
3,825
+4.74%
|
-
|
Feb 18
2025
|
James R. Kasinger General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
9,595
-11.62%
|
$508,535
$53.85 P/Share
|
Feb 18
2025
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,640
-5.58%
|
$640,200
$55.05 P/Share
|
Feb 18
2025
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,250
+5.97%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 157K shares |
---|---|
Open market or private purchase | 7K shares |
Bona fide gift | 100K shares |
---|---|
Open market or private sale | 165K shares |